NEW YORK, July 28, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: GlaxoSmithKline PLC (NYSE: GSK), Sanofi (NYSE:
SNY), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), TherapeuticsMD
Inc. (AMEX: TXMD), and Aoxing Pharmaceutical Company Inc. (AMEX:
AXN). Free research report on GlaxoSmithKline can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=GSK On
Monday, July 27, 2015, the NASDAQ
Composite ended at 5,039.78, down 0.96%, the Dow Jones Industrial
Average lost 0.73%, to finish the day at 17,440.59, and the S&P
500 closed at 2,067.64, down 0.58%. The losses were broad based as
eight out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
GlaxoSmithKline PLC's stock edged 0.51% higher, to close the day
at $41.60. The stock recorded a
trading volume of 2.64 million shares, below its three months
average volume of 4.00 million shares. Over the last one month and
over the past three months, GlaxoSmithKline PLC's shares have
fallen by 4.39% and 10.06%, respectively. However, the stock has
advanced 0.05% since the start of this year. The company's shares
are trading 3.65% below their 50-day moving average. Additionally,
GlaxoSmithKline PLC traded at a PE ratio of 6.36 and has a Relative
Strength Index (RSI) of 37.23. Sign up and read the free notes on
GSK at:
https://www.EquityResearchInstitute.com/reports?keyword=GSK
On Monday, shares in Sanofi recorded a trading volume of 0.92
million shares, lower than their three months average volume of
1.69 million shares. The stock ended the day 0.39% lower at
$53.33. Shares of the company traded
at a PE ratio of 29.63. Sanofi's stock has advanced 3.57% in the
last one month, 5.41% in the previous three months and 20.82% on
YTD basis. The company is trading above its 50-day and 200-day
moving averages by 5.18% and 11.21%, respectively. Furthermore,
shares of Sanofi have an RSI of 61.60. The complimentary notes on
SNY can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=SNY
Aerie Pharmaceuticals Inc.'s stock edged 0.38% lower, to close
Monday's session at $18.55. The stock
recorded a trading volume of 0.34 million shares, below its three
months average volume of 1.31 million shares. Over the last one
month and the previous three months, Aerie Pharmaceuticals Inc.'s
shares have advanced 0.71% and 73.36%, respectively. However, the
stock has declined 36.45% since the start of this year. The company
is trading 18.25% above its 50-day moving average. Further, Aerie
Pharmaceuticals Inc.'s stock has an RSI of 56.99. Register for free
on Equity Research Institute and access the latest research on AERI
at:
https://www.EquityResearchInstitute.com/reports?keyword=AERI
TherapeuticsMD Inc.'s stock finished Monday's session 0.86%
higher at $8.23. A total of 0.61
million shares were traded, which was below its three months
average volume of 1.19 million shares. Over the last one month and
the previous three months, TherapeuticsMD Inc.'s shares have gained
1.60% and 22.11%, respectively. Additionally, the stock has surged
84.94% since the beginning of 2015. The company's shares are
trading above their 50-day and 200-day moving averages by 7.06% and
46.83%, respectively. TherapeuticsMD Inc.'s stock has an RSI of
57.04. The complete research on TXMD is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=TXMD
On Monday, shares in Aoxing Pharmaceutical Co. Inc. ended the
session 3.45% lower at $1.68. The
stock reported a trading volume of 0.20 million shares, below its
three months average volume of 0.99 million shares. Although,
Aoxing Pharmaceutical Co. Inc.'s shares have lost 8.20% in the last
one month, it has surged 7.69% in the previous three months and
425.00% on YTD basis. The stock is trading 58.90% above its 200-day
moving average. Moreover, shares of Aoxing Pharmaceutical Co. Inc.
have an RSI of 52.59. Free in-depth research on AXN is available
at:
https://www.EquityResearchInstitute.com/reports?keyword=AXN
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com